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Abstract
Background: Bluetongue is a disease of domestic and wild ruminants caused by bluetongue virus serotypes (BTV),
which have caused serious outbreaks worldwide. Commercially available vaccines are live-attenuated or inactivated
virus strains: these are effective, but there is the risk of reversion to virulence or reassortment with circulating strains
for live virus, and residual live virus for the inactivated vaccines. The live-attenuated virus vaccines are not able to
distinguish naturally infected animals from vaccinated animals (DIVA compliant). Recombinant vaccines are
preferable to minimize the risks associated with these vaccines, and would also enable the development of
candidate vaccines that are DIVA-compliant.
Results: In this study, two novel protein body (PB) plant-produced vaccines were developed, Zera®-VP2ep and
Zera®-VP2. Zera®-VP2ep contained B-cell epitope sequences of multiple BTV serotypes and Zera®-VP2 contained the
full-length BTV-8 VP2 codon-optimised sequence. In addition to fulfilling the DIVA requirement, Zera®-VP2ep was
aimed at being multivalent with the ability to stimulate an immune response to several BTV serotypes. Both these
candidate vaccines were successfully made in N. benthamiana via transient Agrobacterium-mediated expression, and
in situ TEM analysis showed that the expressed proteins accumulated within the cytoplasm of plant cells in dense
membrane-defined PBs. The peptide sequences included in Zera®-VP2ep contained epitopes that bound antibodies
produced against native VP2. Preliminary murine immunogenicity studies showed that the PB vaccine candidates
elicited anti-VP2 immune responses in mice without the use of adjuvant.
Conclusions: These proof of concept results demonstrate that Zera®-VP2ep and Zera®-VP2 have potential as BTV
vaccines and their development should be further investigated.
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Background
Bluetongue (BT) is a non-contagious, arthropod-borne
viral disease that affects ruminants [1]. BT was first recog-
nised and described in South Africa after the introduction
of fine-wool sheep from Europe over 200 years ago [2, 3].
The classical form of BT is seen in sheep; however, cattle
are also a natural reservoir for the virus [1]. The causative
agent of BT is bluetongue virus (BTV), the type species of
the genus Orbivirus in the family Reoviridae [4]. BTV is
mostly transmitted by adult females of the haematopha-
gous midges that belong to the genus Culicoides [5].
Since 1998 BTV has become one of the most wide-
spread animal pathogens, as it has spread to areas that
were previously free of the virus [6]. Outbreaks of BT
occur when susceptible sheep are introduced into BTV-
endemic regions or when the virus spreads to naïve
sheep populations at the interface of endemic and non-
endemic regions [7]. In 2006 BTV serotype 8 (BTV-8)
was detected in northern Europe (Netherlands, Belgium,
Germany and the north of France); this was the first
time that BTV had been detected beyond the latitude of
52 °N. In subsequent outbreaks the northernmost limits
of BTV moved beyond 54 °N [2, 8].
A number of vaccines have been developed against
BT. These include inactivated whole virus vaccines, live
attenuated virus vaccines (modified live virus vaccines),
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recombinant vaccines and virus-like particle (VLP) vac-
cines. While these vaccines have various advantages and
disadvantages, only attenuated virus vaccines and some
inactivated vaccines are presently commercially available
[9–12]. A vaccine produced by Onderstepoort Biological
Products (OBP, Pretoria, South Africa) that consists of a
mixture of attenuated field strains is widely used in
South Africa [13, 14]. However, several side effects in-
cluding the development of mild clinical symptoms [15],
decreased milk production [9] and transplacental infec-
tion [16, 17] have been documented with the use of
these vaccines. These factors have led to the develop-
ment of recombinant BTV vaccines. VLP vaccine candi-
dates have been produced using insect cells and more
recently, also plant-based expression systems, and were
shown to be safe and effective, with vaccinated sheep
protected against virus challenge [18–20]. A disadvan-
tage of these however, is that they are protective against
only one of the 27 BTV serotypes, unless they are ad-
ministered as a combination of VLPs produced against
different serotypes, thereby increasing cost of the vac-
cines. Furthermore, with the use of VLP vaccines, one is
not able to distinguish infected from vaccinated animals
(DIVA) when using current commercially available diag-
nostic techniques which rely on the detection of the
group specific antigen VP7, [2, 21, 22]. In South Africa
22 of the 27 known BTV serotypes have been detected
in the country and it has been found that multiple BTV
serotypes co-circulate with each vector season [13]: this
demonstrates the necessity for use of a multivalent vac-
cine for BTV in this region.
The BTV structural protein VP2 is the major serotype-
specific antigen of BTV [14, 23]. It has been shown
that ≥ 50 μg doses of VP2 obtained from both isolated
and purified BTV as well as recombinantly-produced
VP2 induced neutralising antibodies protected some, but
not all of the sheep that were vaccinated, against viral
challenge [14, 24]. Even though these subunit vaccines
have been shown to be safe for use in sheep [14], it is
desirable to enhance the breadth of immunogenicity of
these vaccine candidates.
Epitopes are localised regions on the surfaces of anti-
gens that are involved in recognition by antibodies.
These regions also have the ability to elicit an immune
response and represent the smallest subunits that can be
used therapeutically [25, 26]. Many advantages such as
safety, ease of production and analytical control are as-
sociated with the use of epitope-based vaccines: with the
presentation of specific epitopes a precise immune re-
sponse can be directed at conserved and highly im-
munogenic regions of antigens of interest [25]. B-cell
epitopes are parts of antigens that are recognised by the
variable regions of antibodies [27]. Several epitope-based
vaccines have been developed for the treatment of
various cancers and the prevention of infectious diseases.
Epitope-based vaccines for the treatment of ovarian car-
cinoma, end-stage cervical cancer and melanoma have
been successful and have entered or completed phase I
and II clinical trials [28–30]. Furthermore, an epitope-
based vaccine derived from the Epstein-Barr virus
latency-related antigens has been shown to be immuno-
genic in pre-clinical trials in mice [31].
The immunogenicity of proteins can be increased by
fusion to other immunogenic proteins, such as the hepa-
titis B core protein [32, 33], by adding adjuvant to the
vaccine formulation [34], or by fusion to signal se-
quences that drive assembly and sequestration of the
protein into protein bodies (PBs) [35]. Particulate pro-
teins with repeating sequence motifs, such as PBs, are
favoured for uptake by antigen presenting cells, thereby
enhancing the immune response [36].
PBs are endoplasmic reticulum (ER)-derived organelles
found in maize seeds. These organelles stably store
massive amounts of zeins as a source of protein within
the ER [37]. Once expressed and targeted to the ER for
post translational modification, these zein polypeptides
oligomerise in large complexes and eventually self-
associate into PBs [38–40]. The proline-rich N-terminal
(including a tandem-repeat domain) of one of these
zeins - γ-zein - was shown to be important for ER reten-
tion and the formation of PBs in both maize seeds and a
wide range of eukaryotic cells [41].
Zera® (ZIP Solutions, Spain) is a synthetic peptide gen-
erated from the N-terminal proline-rich domain of γ-
zein [41]. The Zera® sequence consists of 112 amino
acids that include the γ-zein signal peptide and the first
93 amino acids of γ-zein. The complete Zera® sequence
contains four regions: a γ-zein ER-targeting signal peptide,
11 hydrophobic non-proline amino acids that contain a
CGC motif that is important for packing of protein bodies
due to the formation of inter-and intra-chain disulphide
bonds, the proline-rich repeat domain containing eight re-
peats of the hexapeptide PPPVHL which is important for
the assembly of PBs and finally, a proline-X (Pro-X region)
sequence where proline residues alternate with other
amino acids [41, 42]. The main driving forces behind the
self-assembly of PBs are hydrophobic interactions between
the (PPPVHL)8 repeat regions of two or more Zera® chains
and inter-chain disulphide bond formation that stabilises
and strengthens the oligomers [42].
Zera® fused to several different proteins - including red
fluorescent protein [43], enhanced cyan fluorescent protein
[44], human growth hormone [44], calcitonin [41] and epi-
dermal growth factor [45] - has been shown to result in the
formation of PBs in the leaves of both transiently and stably
transformed tobacco plants. It has been shown that fusion
of a HPV-16 shuffled E7 protein (E7sh) to Zera® enhanced
immunogenicity of the protein; moreover, free protein
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bodies mixed with free E7sh protein also resulted in an en-
hanced immune response [36, 46]. More recently, a study
by Hofbauer et al. [47] showed that encapsulation of
hemagglutinin in PBs resulted in stronger immune re-
sponses in mice when compared to responses obtained
with soluble antigen.
The antigenic characteristics of BTV VP2 make it an
excellent candidate for a BT vaccine. By presenting VP2
to the immune system in particulate form, immunogen-
icity of the protein should be enhanced, and less of the
antigen may be needed for vaccination. Here we report
on the development of two novel VP2-based BTV vac-
cine candidates. For the first vaccine candidate, the puta-
tive antibody-binding epitopes of multiple serotypes of
VP2 were predicted with in silico methods and a synthetic
peptide based on the predicted epitopes was constructed.
The second vaccine candidate consisted of the full-length
plant codon-optimised BTV-8 VP2. Nucleotide sequences
representing both the synthetic epitope sequence and the
full-length plant codon-optimised BTV-8 VP2 were fused
to the Zera®-encoding sequence to drive PB formation
when expressed in N. benthamiana. In situ TEM analysis
of infiltrated leaves was carried out to determine if the
Zera®-fused proteins accumulated into PBs. Finally, a pre-
liminary investigation was carried out to assess the im-
munogenicity of these fusion proteins in mice.
Results
Prediction of a putative BTV VP2 epitope
In silico prediction of continuous B-cell epitopes was
carried out on eight full-length VP2 amino acid se-
quences that were available on GenBank at the time of
the study (http://www.ncbi.nlm.nih.gov/genbank) with
COBEpro [27] prediction software available from the
Scratch protein server (http://scratch.proteomics.ics.u-
ci.edu/). The 8 VP2 amino acid sequences were aligned
and two predicted B-cell epitope regions that were similar
for most of the serotypes were selected for the epitope-
based vaccine sequence, these epitope regions were not
similar to the neutralisation regions (R1 and R2) proposed
by deMaula et al. [48]. Two predicted epitope regions
(Fig. 1a, blue and green boxes) that showed consensus
among most of the amino acid sequences were selected
for the design of the putative epitope-based vaccine and a
Fig. 1 Construction of VP2ep. a Selected regions of the multiple alignment of 8 selected BTV VP2 serotype amino acid sequences are shown. The
predicted epitope regions corresponding to most of the serotypes are shown below the alignment in bold and boxed in blue and green. The
homologous region is boxed in purple. b The putative amino acid and nucleotide sequences of VP2ep
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homologous region across all the serotypes was also in-
cluded in the sequence (Fig. 1a, purple box). In total the
putative predicted epitope-based oligomer (Zera®-VP2ep)
consisted of 54 bp that translated into 18 amino acids
(Fig. 1b). No linkers were included between the putative
epitope regions to facilitate folding as these were linear B-
cell epitopes that would be folded into Zera® PBs.
Zera®-VP2ep and Zera®-VP2 expression in N. benthamiana
Zera®-VP2ep and Zera®-VP2 were successfully cloned into
pEAQ-HT (George Lomonossoff, JII, Norwich) to gener-
ate pEAQ-HTZera®-VP2ep (Additional file 1: Figure S2a)
and pEAQ-HTZera®-VP2 (Additional file 1: Figure S2c)
and the recombinant constructs electroporated into Agro-
bacterium tumefaciens LBA4404. Transient expression of
Zera®-VP2ep and Zera®-VP2 after Agrobacterium-medi-
ated infiltration of N. benthamiana leaves was investigated
over a 7 day period, where leaf discs were harvested at 2,
3, 5 and 7 days post infiltration. Plants were infiltrated at
an OD600 of 0.5, 1.0 and 1.5 with recombinant Zera®-
VP2ep or Zera®-VP2 to examine the effects of A. tumefa-
ciens cell concentration on recombinant protein expres-
sion levels. Both proteins were detected on western blots,
with predicted bands of Zera®-VP2ep and Zera®-VP2 at
~16 kDa and ~120 kDa, respectively (Fig. 2a and b).
Zera®-VP2ep accumulation was observed on days 2, 3 and
5, with peak accumulation observed at 3 dpi (Fig. 2a)
when using an infiltration OD600 of 0.5. The infiltrated
leaves showed chlorosis with slight necrosis at the infiltra-
tion sites at 3 dpi (Fig. 2c – top panel), after which the in-
filtrated leaves became more necrotic. When the cell
concentration was increased to an OD600 of 1.0 and 1.5,
the plants showed severe necrosis with blackening and
drying out of the leaves (Fig. 2c – top panel). In addition
the increased cell concentration resulted in no expression
of Zera®-VP2ep at any of the days sampled post infiltration
(results not shown).
In contrast, expression of Zera®-VP2 was only detected
on western blots by using an infiltration OD600 of 1.5
(Fig. 2b). Expression was observed from 5 dpi onward,
with the highest levels detected at 7 dpi. The high infil-
tration OD resulted in slight chlorosis of the leaves at 7
dpi (Fig. 2c – bottom panel), however it did not nega-
tively affect expression of Zera®-VP2. Even though the
leaves infiltrated at lower cell concentrations (Fig. 2c)
displayed chlorosis, no protein was detected on western
blots (results not shown).
In situ characterisation of PBs
Having shown that optimal expression of Zera®-VP2ep
and Zera®-VP2 occurred at 3 and 7 dpi respectively,
based on protein band intensity on western blots, we de-
termined whether or not these polypeptides were se-
questered into PBs as designed. It has been shown that
the Zera® domain containing the (PPPVHL)8 repeats and
the Pro-X sequences allow for the accumulation of fu-
sion proteins into membrane-bound PBs [45, 49]. TEM
of embedded Zera®-VP2ep and Zera®-VP2 leaf material
at 3 and 7 dpi, respectively, showed the presence of
membrane-defined, spherical electron-dense PB-like
structures ranging from 0.6 μm to 1 μm in size in the
cytoplasm of leaves expressing Zera®-VP2ep and Zera®-
VP2 (Fig. 3a and b, respectively). These electron-dense
structures were embedded in the cytoplasm. No struc-
tures resembling PBs were observed in any of the nega-
tive control samples that were viewed (Fig. 3c).
Purification of PBs
Since it was shown that Zera®-VP2ep and Zera®-VP2 suc-
cessfully formed PB-like structures when expressed in N.
benthamiana, the number of plants infiltrated was
scaled up to purify PBs by ultracentrifugation through a
sucrose cushion. Western blot analysis of the clarified
crude protein extracts showed the presence of bands at
~16 kDa for Zera®-VP2ep (Fig. 4a [i]) and ~120 kDa for
Zera®-VP2 (Fig. 4a [ii]). The detection of an additional
band at ~26 kDa on the Zera®-VP2ep western blot
(Fig. 4a [i], black arrow) could potentially represent
dimerised fusions of Zera®-VP2ep. No bands were de-
tected in the crude extracts from negative control plants
(Fig. 4a [i] and [ii]).
Purification of the PBs using discontinuous sucrose
gradients was not successful as western blot analysis of
the fractions collected after ultracentrifugation showed
the presence of Zera®-VP2ep and Zera®-VP2 in all the
fractions, with the bulk of protein detected in the pellet
(results not shown). This could be because of the vari-
able sizes and therefore densities of the PBs, as well as
the presence of soluble protein in the preparation. Ac-
cordingly, crude Zera®-VP2ep and Zera®-VP2 as well as
negative control plant extracts were overlaid onto 42%
sucrose cushions and centrifuged at 79 000 × g to facili-
tate collection of the dense PBs in the pellet. After cen-
trifugation, the supernatant on top of the sucrose
cushion (Top), the sucrose cushion itself (42% sucrose)
and the resuspended pellets (Pellet) were analysed on
dot blots probed with α-VP2R serum (Fig. 4b). Fractions
collected from the negative control showed no colour
development in either the pellet, the 42% sucrose frac-
tion or the top fraction (Fig. 4b [i]). Dot blots of Zera®-
VP2ep and Zera®-VP2 showed a positive reaction with
the pellet sample, indicating successful pelleting of the
recombinant PBs through the sucrose cushion (Fig. 4b
[ii] and [iii], respectively); no protein was detected in ei-
ther the top or 42% sucrose fractions.
The purified PBs were found to be very stable as well
as insoluble. Dot blot analysis of pelleted Zera®-VP2ep
and Zera®-VP2 always showed the presence of
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oligomerised proteins in the denatured samples, even after
treating the purified proteins at 90 °C with 500 mM DTT
in order to denature them (results not shown). It was
further investigated whether the sequential extraction
process described by Joseph et al. [43] would result in the
solubilisation of the PBs. The first solubilisation step facili-
tates the extraction of soluble and membrane-bound pro-
teins, after which the second step extracts proteins that
are linked by disulphide bridges. The final heating step
should theoretically result in solubilisation of the PB cores
[43]. After treatment with SDS and DTT, the PBs were al-
ways present in the final insoluble pellet (data not shown).
Since the PBs were intended for immunogenic studies in
mice, it was not desirable for the extraction buffers to con-
tain reagents such as DTT or SDS, as these might be det-
rimental to the health of the animals. Therefore, the pellet
obtained after ultracentrifugation was washed with buffer
PBP3 containing 10% sucrose to stabilise the PBs and
Fig. 2 Expression of Zera®-VP2ep and Zera®-VP2 in N. benthamiana. Western blots of crude leaf extracts from leaves infiltrated with Zera®-VP2ep
(a) and Zera®-VP2 (b) constructs at infiltration OD600 values of 0.5 and 1.5, respectively and harvested at 2, 3 5 and 7 days post infiltration (dpi).
Expressed protein was detected with α-VP2R polyclonal antibody. Samples from negative control plants (−) were infiltrated with infiltration
medium only. Red arrows indicate the position of the appropriately-sized expressed proteins. Lanes M represent the molecular weight marker with
sizes indicated in kDa. c N. benthamiana leaves infiltrated with different A. tumefaciens cell concentrations. Leaves expressing Zera®-VP2ep and
Zera®-VP2 were photographed at 3 and 7 dpi, respectively
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protein concentrations of Zera®-VP2ep and Zera®-VP2 PBs
were calculated to be ~ 69.5 mg and ~ 35 mg total protein
per kilogram of fresh leaf material, respectively.
Humoral immune response of PB vaccine candidates
In order to determine whether the purified PBs stimulate
antibodies which are VP2-specific, mice were inoculated
with the Zera®-VP2ep and Zera®-VP2 PB candidate
vaccines at 10 μg per dose and the humoral anti-VP2
immune responses analysed by indirect ELISA, using E.
coli-produced BTV-8 VP2 fused to a trigger factor
chaperone as coating antigen. Initial analysis of the pre-
and final bleed sera of the individual mice showed the
presence of anti-VP2 antibodies in only the final bleed
sera of mice vaccinated with both the Zera®-VP2ep and
Zera®-VP2 candidate vaccines, therefore mouse sera
a b c
Fig. 3 Transmission electron micrographs of protein bodies. Leaf sections were infiltrated with a pEAQ-HTZera®-VP2ep and b pEAQ-HTZera®-VP2
and c infiltration medium as a negative control. PBs for both Zera®-VP2ep (a – blue arrows) and Zera®-VP2 (b – pink arrows) were present as
electron-dense structures within the cytoplasm of the infiltrated leaves. No similar structures were present in the negative control samples (c).
Scale bars: a and b: 0.5 μm; c: 0.2 μm. CW: cell wall, CPT: chloroplast, CYT: cytoplasm, ER: endoplasmic reticulum
a
b
Fig. 4 Purification of PBs. a Western blot analysis of crude Zera®-VP2ep (i) and Zera®-VP2 (ii) extracted protein using α-VP2R as primary antibody.
White arrows indicate the respective proteins with the black arrow showing an oligomerised fusion of VP2ep. In both cases the negative control
(−) was plant material infiltrated with infiltration medium only that was extracted using the same method. Lanes M indicate the molecular weight
marker in kDa. b α-VP2R dot blots of (i) the negative control, (ii) Zera®-VP2ep and (iii) Zera®-VP2 purified using a 42% sucrose cushion
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from each group were pooled (5 mice/vaccine) for ana-
lysis of the anti-VP2 binding titres. The antibody binding
titres (Fig. 5a) are expressed as the reciprocal of the
maximum serum dilution containing absorbance values
that were three times greater than the corresponding
pre-bleed serum at 1:50. No anti-VP2 response was de-
tected for the vaccine pre-bleeds (results not shown)
and the negative control vaccine (DPBS, Fig. 5a). The
positive control indirect ELISA using sheep serum (from
sheep vaccinated with plant-produced BTV-8 VLPs [20])
showed an anti-VP2 response (Fig. 5b), thereby validat-
ing the indirect ELISA used to determine anti-VP2 titres
of the Zera® vaccine candidates tested in this study.
The Zera®-VP2ep vaccine elicited anti-VP2 titres of 800,
with an OD405 of ~0.177 (Fig. 5a, blue line) compared to
an OD405 of ~0.0039 obtained for the corresponding pre-
bleed serum. In addition, the Zera®-VP2 vaccine candidate
elicited anti-VP2 binding titres of 3200 at an OD405 of
~0.0097 (Fig. 5a, pink line), compared to an OD405 value
of ~0.0016 obtained for the corresponding pre-bleed
serum. Statistical analysis of the anti-VP2 responses elic-
ited by the Zera®-VP2ep and Zera®-VP2 vaccine candi-
dates, showed that the antibody levels were significantly
higher for both vaccines compared to the DPBS negative
control (KW; H = 22.002, N = 30, p < 0.0001).
The ability of the antibodies produced against Zera®-
VP2ep and Zera®-VP2 to recognise the BTV-8 VP2 fu-
sion protein was further analysed by evaluating mouse
serum from mice inoculated with Zera®-VP2ep and
Zera®-VP2 vaccine candidates on western blots using the
E. coli-produced BTV-8 VP2 fusion protein as antigen.
Individual pre-and final bleed sera from both experi-
ments were pooled for each vaccine candidate and ana-
lysed for anti-VP2 responses (Fig. 5c).
The E. coli-expressed VP2 fusion protein (~163 kDa,
white arrow) was detected with the positive control
sheep serum raised against plant-produced BTV-8
VLPs and the final bleed serum obtained from Zera®-
VP2ep- and Zera®-VP2-vaccinated mice (Fig. 5c). Non-
specific protein bands smaller than the ~163 kDa VP2
band were detected with all the serum samples, in-
cluding the positive control. These bands possibly rep-
resent truncated versions of the E. coli-expressed VP2.
It has been shown that heterologous expression in E.
coli often results in the expression of truncated
versions of the expressed proteins due to abundant co-
dons found in heterologous genes which cause transla-
tional stalling and termination of protein expression
[50]. No non-specific protein bands were detected
with the pre-bleed sera.
a b
c
Fig. 5 Analysis of serum from immunised mice. a Titration of the mouse antisera produced Zera®-VP2ep (blue line), Zera®-VP2 (pink line) and DPBS
(negative control, grey line) vaccine candidates as well as titration of positive control sheep serum produced against BTV-8 VLPs [20] to validate the
indirect ELISA (b). The markers indicate the mean value of triplicate samples from both animal experiments, and error bars indicate the
standard deviation. (c) Western blot detection of the E. coli-expressed VP2 fusion protein with 1:100 dilution of pooled mice sera from
animals vaccinated with the Zera®-VP2ep and Zera®-VP2 vaccines. Lane M represents the molecular weight marker. The negative control
(−) was performed with no primary antibody and sheep serum obtained from BTV-8 VLP vaccinated sheep [20] was used as the positive
control (+). Lanes PB and FB represent the pre-and final bleed sera respectively. The white arrow indicates the E. coli-expressed VP2 fusion
protein at ~163 kDa. PB – prebleed; FB – final bleed
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Discussion
The incursion of BTV-8 into northern Europe in 2006
resulted in significant economic losses due to the mor-
tality of affected livestock, but more importantly due to
the ban of ruminant trade between affected and non-
affected regions [51]. In an effort to limit the direct losses
incurred with BTV infection and to minimize circulation
of the virus, vaccination of livestock using four mon-
ovalent modified live virus vaccines obtained from South
Africa was undertaken by European countries [9, 11].
Many vaccine candidates have been developed against BT
– with varying degrees of success [19]. Recombinant vac-
cines are promising vaccine candidates as they have the
potential to be safer than attenuated vaccines with no risk
of reassortment, and they can be DIVA compliant [52, 53].
Immunologically, VP2 is the most important BTV pro-
tein [54–58], and inocula consisting of VP2 on its own
or combined with VP5 have been tested as possible vac-
cine candidates, with variable results [11, 59]. Even
though VP2 subunit vaccines provided protection at
lower doses, no neutralising antibodies were detected
after vaccination. It is therefore desirable to increase im-
munogenicity of these vaccine candidates; this could po-
tentially be achieved by fusion of VP2 to Zera® which
results in formation of particulate proteins which are
partly protected from extracellular enzymatic degrad-
ation. These particulate proteins indirectly or directly
target antigen presenting cells (APCs) by either acces-
sing the specific endosomal uptake function of APCs or
by interaction with specific dendritic cells, thereby en-
hancing the immune response [60]. Moreover, it has
been postulated that the N-terminus of Zera® potentially
possesses intrinsic adjuvant activity, thereby further en-
hancing the immune response [35, 36, 47, 61].
In an effort to find alternative, possibly multivalent
vaccine candidates for BTV, we undertook to design and
express two novel second-generation BTV vaccines in N.
benthamiana by means of Agrobacterium-mediated
transient recombinant protein expression. The first vac-
cine is based on synthetic B-cell epitopes predicted for
multiple serotypes of VP2 by using online computational
methods; the second vaccine is based on incorporation
of the full length BTV-8 VP2 only. By utilising the im-
munogenic properties of only VP2, these vaccine candi-
dates were aimed at being DIVA-compliant using
current commercially available serological diagnostic
tests which are dependent on detecting the presence of
the group-specific antigen VP7 [2, 22].
The putative multi-epitope (VP2ep) and full length
BTV-8 VP2 were both fused to Zera® to induce accumu-
lation of the proteins in dense PBs called StorPro® or-
ganelles (ZIP Solutions, Spain). Both Zera®-VP2ep and
Zera®-VP2 proteins were successfully expressed in
plants, and it was shown using TEM that both these
constructs directed the accumulation of BTV-specific
proteins in electron-dense granules that were sur-
rounded by a membrane, within the cytoplasm of plant
cells. These structures were similar in size and morph-
ology to epidermal growth factor PBs produced in SF9
insect cells [45]. Two steps have been described for the
formation of PBs: (i) early synthesized Zera® fusion poly-
peptide chains promote self-assembly of Zera®, resulting
in the origin of PBs and thereafter (ii) the continued syn-
thesis of the fusion protein at later stages results in the
PB growing by incorporating Zera® fusions into the PBs
that were formed during the early stages of expression
[42]. The different sizes that were observed for the
Zera®-VP2ep and Zera®-VP2 PBs could be attributed to
the occurrence of the two-step process described above.
We attempted to purify Zera®-VP2ep and Zera®-VP2
PBs on discontinuous sucrose gradients. Analysis of the
fractions collected after ultracentrifugation showed that
the proteins of interest were present in all the fractions,
including the pellet. These results could be attributed to
the different sizes and therefore densities of early and
mature protein bodies. Similar results were obtained by
Geli et al. [49] after subcellular fractionation of trans-
genic plants expressing γ-zein. Therefore, a 42% sucrose
cushion was used instead to pellet the PBs in the plant
extract, this made the PBs very easy to partially purify.
The pelleted PBs were extremely stable and insoluble,
even after treatment with SDS, DTT and heat. The se-
questration of proteins in PBs that are membrane-
delimited has been shown to protect fusion proteins
from proteolytic degradation [45]. The stability of the
PBs is ideal for vaccines, as it means the vaccine candi-
dates can be stored at 4 °C for extended periods of time
without the risk of degradation or proteolysis.
Both the Zera®-VP2ep and Zera®-VP2 fusion proteins
were successfully detected with rabbit serum raised
against the full-length VP2 fusion protein. These results
showed that antibodies in the sera were able to recognise
and bind to the synthetic epitope, suggesting that regions
encoding immunogenic epitopes were accurately selected
for design of this vaccine candidate. These results are
promising, as success of the epitope-based vaccine could
obviate the need for vaccination with a mixture of mul-
tiple serotypes since it contains putative epitopes for at
least eight BTV serotypes.
Preliminary tests to analyse the immunogenicity of the
Zera®-VP2ep and Zera®-VP2 candidate vaccines were car-
ried out in mice. This proof of concept study showed that
both the Zera®-VP2ep and Zera®-VP2 candidate vaccines
elicited significant anti-VP2 humoral immune responses
when compared to the negative control. Moreover, the re-
action of the antibodies in both ELISA and western blots
means the antibodies elicited in vaccinated mice would
bind native protein as well as denatured protein, meaning
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they have the potential to protect against infection. Future
experiments, such as neutralization assays and challenge
experiments of immunized animals, have to be carried out
in order to further characterize the immune response ob-
tained with these vaccine candidates.
Conclusions
In summary, Zera®-VP2ep and Zera®-VP2, two novel
protein body vaccine candidates encoding the predicted
putative B-cell epitopes of VP2 and full-length codon-
optimised VP2 fused to Zera® to make particulate vaccines
were successful in eliciting anti-VP2 humoral immune re-
sponses in mice. These novel PB vaccine candidates have
shown great potential in this proof of concept study for
the use of BTV vaccines, as they are quick and simple to
produce, extremely stable and DIVA compliant, making
them ideal as rapid response vaccines.
Methods
In silico epitope prediction of VP2 and construction of the
fusion product Zera®-VP2ep
Eight full-length BTV VP2 amino acid sequences (BTV-1:
ADI79209; BTV-2: CA079950; BTV-6: ADI49552; BTV-8:
AM498052; BTV-10: JN704634; BTV-13: AAX48783;
BTV-17: AAB30550 and BTV-23: AAA56867) for proof of
concept were selected from GenBank and the most likely
epitopes of each of these sequences were predicted with
COBEpro [[27], http://scratch.proteomics.ics.uci.edu/], an
online program for the prediction of continuous B-cell
epitopes. The VP2 amino acid sequences were aligned
using ClustalW2 (https://www.ebi.ac.uk/Tools/msa/clus-
talw2/) and two predicted B-cell epitope regions whose
amino acid compositions corresponded to most of the
aligned VP2 sequences were selected for inclusion into
the synthetic epitope-based vaccine. A third homologous
region was also included in the synthetic epitope-based
vaccine sequence.
The plasmid pZera®1 [45] obtained from ZIP Solutions
was used as a template for the PCR amplification of
Zera®. Primers were designed to introduce 5′ AgeI and
3′ NcoI restriction enzyme sites to the gene termini
(Table 1; Zera®-FP and Zera®-RP).
The putative multi-epitope sequence - VP2ep - was de-
signed to contain 5′ MluI and 3′ XmaI restriction enzyme
sites. Two oligomers - VP2ep-F and VP2ep-R (Table 1) -
consisting of 41 bp each were designed and synthesized
with 12 complementary base pairs to facilitate fusion of the
fragments during assembly PCR to yield VP2ep. The as-
sembly PCR reaction consisted of 1 μM each of VP2ep-F
and VP2ep-R, 200 μM dNTPs, 1× Buffer A (Kapa Biosys-
tems) and 1 U KAPA Taq DNA polymerase (Kapa Biosys-
tems). The two oligomers were assembled by initial
denaturation of the DNA at 94 °C for 5 min, followed by
20 cycles of denaturing at 93 °C for 1 min and annealing
and elongation at 65 °C for 30 s. A final elongation step
was carried out for 5 min at 72 °C.
Zera® was fused to VP2ep with a short universal pep-
tide linker - EAAAK (Table 1). Linker primers contain-
ing regions that were complementary to both the linker,
Zera® and VP2ep were designed (Table 1; Linker-VP2ep-
FP and Linker-Zera®-RP) to facilitate assembly of the
fusion product.
Assembly PCR of Zera®-VP2ep was carried out in two
stages. Additional file 2: Figure S1 illustrates the fusion
product Zera®-VP2ep, including the primers that were
used in first and second stage assembly PCR reactions.
The first stage PCR reaction consisted of 50 ng of each
of the following DNA templates: Zera®, VP2ep and the
Table 1 Primers and oligomers used for PCR of individual genes and the assembly PCR of fusion products
Gene/Oligomer Size (bp) Primer Restriction
sites (5′ / 3′)
5′ – 3′ sequencea Tm (°C)
Zera® 352 Zera®-FPb,c Zera®-RP AgeI NcoI GCACCGGTATGAGGGTGTTGCTCGTT 62.7 58.3
GCCCATGGCTGGCACGGGCTTGGAT
VP2ep 70 VP2ep-F VP2ep-R MluI XmaI GCACGCGTTTCCCAGAGCACCTTCGACACGATGTAACAAAT 76.7 79.8
GCCCCGGGTCCACGCAGGCAGGGATACGGATTTGTTACATC
Linker NcoI/MluI CCATGGGAAGCGGCGGCGAAAACGCGT 75.9
Linker-VP2ep-FPb GAAGCGGCGGCGAAAACGCGTTTCCCAGAGCACCTT 77.3
Linker-Zera®-RPb TTTCGCCGCCGCTTCCCATGGTCTGGCACGGGCTTG 81.4
VP2ep-RPb,c XmaI GCCCCGGGTCCACGCAGGCAGGG 56.8
VP2 ~2800 cTPVP2coF MluI GTGGACGCGTTAGGTGCATGGAAGAACTCGCTATCCCAA 56
cVP2coR XhoI GCCTCGAGTCAAACGTTGAGGAGCTTAGTAAG 54
Sequencing primers pEAQ-FP pEAQ-RP GACGAACTTGGAGAAAGATTGTTAAGC 61.2 62.3
AACCAGAGTTAAAGGCCTCGAGC
aThe restriction enzyme sites are underlined and in bold
b,cPrimers used for first and second stage assembly PCR of Zera®-VP2ep
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linker. The remainder of the reaction contained 1 μM of
each primer (Zera®-FP, Linker-VP2ep-FP, Linker-Zera®-
RP, VP2ep-RP), 200 μM dNTPs, 1× Buffer A and 1 U
KAPA Taq DNA Polymerase. PCR was carried out with
an initial denaturing step at 94 °C for 2 min, followed by
25 cycles of denaturing at 93 °C for 1 min and annealing
and elongation at 72 °C for 30 s. A final elongation step
was carried out for 5 min at 72 °C. The assembled PCR
product was used as a template in the second stage PCR.
The second stage PCR reaction contained 50 ng of the
template DNA, 1 μM each of Zera®-FP and VP2ep-RP,
200 μM dNTPs, 1× Buffer A and 1 U KAPA Taq DNA
Polymerase. Second stage cycling conditions were simi-
lar to the first stage assembly PCR conditions, however
only 20 cycles of amplification were carried out and the
annealing temperature was decreased to 65 °C.
Cloning into the plant-expression vector pEAQ-HT
Zera®-VP2ep was directionally cloned into the pEAQ-HT
[62] plant expression vector using AgeI and XmaI res-
triction enzyme sites to yield pEAQ-HTZera®-VP2ep
(Additional file 1: Figure S2a). DH5-α chemically compe-
tent E. coli cells (E. cloni™, Lucigen) cells were transformed
[63] with the plasmid construct and recombinant clones
were selected using kanamycin resistance (50 μg/mL). Re-
combinant clones were screened by colony PCR using
Zera-FP and VP2ep-RP primers. Recombinant clones were
verified by sequencing with pEAQ-HT primers (Table 1).
The full length BTV-8 VP2 gene sequence was codon-
optimised for expression in N. benthamiana in a previ-
ous study [64]. BTV-8 VP2 was excised from the vector
backbone using restriction enzyme digestion with MluI
and XhoI. Likewise, VP2ep was excised from the plasmid
pEAQ-HTZera®-VP2ep (Additional file 1: Figure S2b) so
that it could be replaced with BTV-8 VP2 to create
pEAQ-HTZera®-VP2 (Additional file 1: Figure S2c). Plas-
mids were transformed into E. coli as described above
and recombinant clones were screened by colony PCR
using VP2 gene-specific primers (Table 1). The recom-
binant plasmid was verified by sequencing with the
pEAQ-HT primers (Table 1).
A. tumefaciens-mediated transient expression of Zera®-
VP2ep and Zera®-VP2
pEAQ-HTZera®-VP2ep and pEAQ-HTZera®-VP2 were
transformed into electrocompetent Agrobacterium tume-
faciens LBA4404 using the method described by Maclean
et al. [65]. Transformants were selected on Luria Bertani
(LB) media plates containing 30 μg/mL kanamycin and
50 μg/mL rifampicin. Successful transformation was con-
firmed with colony PCR.
Starter cultures of A. tumefaciens harbouring the
pEAQ-HTZera®-VP2ep and pEAQ-HTZera®-VP2 plas-
mids were supplemented with 30 μg/mL kanamycin,
50 μg/mL rifampicin and 2 mM MgSO4 and grown in
LB media as described by Maclean et al. [65]. The starter
cultures were used to inoculate induction medium sup-
plemented with 30 μg/mL kanamycin, 50 μg/mL rifam-
picin, 20 μM acetosyringone and 2 mM MgSO4. The
cultures were propagated O/N at 27 °C with agitation,
after which the cells were prepared for syringe infiltration
into six-week-old N. benthamiana leaves. Time-trials were
carried out to evaluate at what cell density and which day
the best expression of Zera®-VP2ep and Zera®-VP2 oc-
curred, after which expression was scaled up.
In situ TEM of Zera®-VP2ep and Zera®-VP2 PBs
Recombinant pEAQ-HTZera®-VP2ep or pEAQ-HTZera®-
VP2 plasmids were syringe-infiltrated into six-week-old N.
benthamiana plants and protein was expressed for 3 and
7 days, respectively.
Embedding and sectioning of the leaf material was car-
ried out according to the method described by van Zyl
et al. [64]. Grids were viewed using a Technai G2 trans-
mission electron microscope (FEI).
Screening for Zera®-VP2ep and Zera®-VP2 expression in
N. benthamiana
For small-scale expression three leaf discs were har-
vested at 2, 3, 5 and 7 dpi and ground up in liquid nitro-
gen. The leaf material was resuspended in 70 μL per disc
of buffer PBP3 (100 mM Tris [pH8], 50 mM KCl, 6 mM
MgCl2, 10 mM EDTA, 0.4 M NaCl and 1× Complete
Mini EDTA-free protease inhibitor cocktail [Roche]).
The leaf extracts were clarified for 5 min at 15 000 × g
on a bench top centrifuge.
After large scale expression of Zera®-VP2ep and Zera®-
VP2, leaves were harvested at 3 and 7 dpi, respectively
and was homogenised with a Waring-type blender in
five volumes ice cold PBP3 buffer containing 10% su-
crose and 1 × Complete Mini EDTA-free protease in-
hibitor cocktail. The crude plant extract was incubated
for 1 h at 4 °C with gentle agitation, after which it was
filtered through Miracloth™ (Merck) and further clarified
by centrifugation at 10 000 × g for 10 min at 4 °C.
Purification of protein bodies (PBs)
The clarified crude plant extract was overlaid onto 5 mL of
a 42% sucrose cushion prepared in buffer PBP3 and ultra-
centrifuged for 2 h at 79 000 × g (Beckman SW32Ti rotor)
at 4 °C. The pellet containing PBs was resuspended in
300 μL buffer PBP3 containing 10% sucrose. Purified PBs
were stored at 4 °C. Total protein yield was quantified using
the DC Protein Assay (Bio-Rad) according to the manufac-
turer’s instructions.
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E. coli-based expression of BTV-8 VP2 and antibody pro-
duction in rabbits
Since there is no commercially available antibody for
BTV VP2, the BTV-8 VP2 protein (~163 kDa) was
expressed as a fusion product with a trigger factor
chaperone and a translation enhancing element to
achieve high level, soluble expression in E. coli (http://
www.takara-bio.com). The BTV-8 VP2 fusion protein
was expressed for 24 h using the pCold™TF Cold Shock
Expression System (TAKARA) according to the manu-
facturer’s instructions. Inclusion bodies were purified
from the E. coli cell pellet using Bugbuster® (Novagen,
USA) according to the manufacturer’s instructions. For
antibody production in rabbits, the resuspended VP2 fu-
sion protein inclusion bodies were dialysed O/N at 4 °C
using dialysis tubing with a molecular weight cut-off of
10 kDa (Thermo Fischer Scientific, USA) in 2 L sterile
Dulbecco’s Endo-free PBS (Sigma-Aldrich, USA). The
VP2 fusion protein was quantified with gel densitometry
using a bovine serum albumin (BSA, Sigma-Aldrich)
protein standard.
Deltamune (Pty) Ltd. (South Africa) carried out inocula-
tion and production of the polyclonal antibody in rabbits,
protocols were approved by the Deltamune Animal Ethics
Committee prior to being carried out. For the primary
inoculation rabbits were injected subcutaneously with
32 μg of the BTV-8 VP2 fusion protein in the presence of
Incomplete Freund’s Adjuvant (IFA, Difco, #263910). This
was followed by three subsequent booster vaccinations (in
the presence of IFA); the first booster was administered
two weeks after the initial injection and thereafter the sec-
ond and third boosters followed one week after the other.
Rabbit serum (α-VP2R) obtained from Deltamune was
used as primary antibody for western– and dot blot ana-
lysis of Zera®-VP2ep and Zera®-VP2.
Western and dot blot analysis of Zera®-VP2ep and Zera®-
VP2
For western blot analysis, the plant extracts were incu-
bated at 90 °C for 10 min in 5 × DTT sample application
buffer (250 mM Tris-Cl [pH6.8], 500 mM DTT, 10% so-
dium dodecyl sulphate [SDS], 0.3 mM bromophenol
blue and 10% glycerol). Zera®-VP2ep and Zera®-VP2 pro-
teins were separated on 15 and 8% SDS polyacrylamide
gels, respectively, and transferred onto nitrocellulose by
semi-dry electroblotting. Dot blots were carried out to
detect purified PBs. A volume of 5 μL of the purified
protein was dropped onto nitrocellulose membranes and
dried completely, after which dotblots were treated the
same as western blots.
Zera®-VP2ep and Zera®-VP2 was detected with using a
1: 2000 dilution rabbit-raised anti-VP2 (BTV-8)
polyclonal antibody (α-VP2R). These antibodies were de-
tected with 1:5000 alkaline phosphatase-conjugated anti-
rabbit antibody (Sigma-Aldrich). Detection was per-
formed using BCIP/NBT (KPL) substrate.
Immunization of mice
Approval for this study was granted by the Animal Re-
search Ethics Committee at the University of Cape Town
(AEC# 011–016). Female BALB/c mice (6–8 weeks old,
obtained from South African Vaccine Producers) were
subcutaneously immunised with the partially purified
Zera®-VP2ep and Zera®-VP2 candidate vaccines at 10 μg
per dose (5 mice per vaccine). Dulbecco’s Phosphate
Buffered Saline (DPBS, Sigma) was used as a negative
control. Pre-bleeds were collected prior to vaccination
(day 0) and mice were boosted on Day 28 with doses
containing 10 μg of the appropriate antigens. Final
bleeds were obtained via cardiac puncture at Day 56.
The immunization study was repeated twice.
Indirect ELISA for detection of anti-VP2 antibodies
The BTV-8 VP2 fusion protein was expressed and ex-
tracted according to the method described above for
antibody production. The fusion protein was used as
coating antigen in indirect ELISAs to test mouse serum
and serum obtained from sheep vaccinated with BTV-8
VLPs [20] was used as positive control primary antibody
to validate the ELISA.
The anti-VP2 response of the candidate vaccines was
determined by indirect ELISA. Ninety-six-well Maxi-
sorp® microtitre plates (Nunc) were coated with 100 μL/
well (1 μg) of the E. coli-produced BTV-8 VP2 fusion
protein diluted in coating buffer (10 mM Tris, pH 8.5)
and incubated O/N at 4 °C. The plates were blocked
with TBS blocking buffer (5% non-fat dry milk in 1 ×
TBS [50 mM Tris, 150 mM NaCl, pH 7.5]) for 2 h at
room temperature after which it was washed with 1 ×
TST buffer (1 × TBS (pH 7.5), 0.05% Tween®20). To
evaluate the anti-VP2 immune response elicited by each
mouse, the pre- and final bleed sera were diluted 1:50 in
100 μL TBS blocking buffer and incubated for 2 h at room
temperature. Plates were washed with 1 × TST buffer and
100 μL goat anti-mouse IgG alkaline phosphatase conju-
gate (1:10 000, Sigma) diluted in blocking buffer was
added per well and incubated for 1 h at 37 °C. After incu-
bation the plates were washed with 1 × TBS (pH 9) buffer
and 200 μL SIGMAFAST™ p-Nitrophenyl phosphate
(pNPP, Sigma) to detect the secondary antibody. The
plates were developed in the dark for 30 min after which
the absorbance was read at 405 nm.
To determine the anti-VP2 binding titres, mouse sera
from vaccine candidates were pooled into vaccine
groups (5 mice/vaccine) for analysis. Final bleed mouse
sera were diluted in TBS blocking buffer in a 4-fold
series in triplicate ranging from a 1:50 dilution to 1:51
200. Mouse sera from the mice vaccinated with DPBS
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served as a negative control. Positive control wells to val-
idate the ELISA contained sheep serum [20] and blank
wells with no antibody were included for background con-
trol in all the ELISAs. The indirect ELISA was carried out
as described above and the anti-VP2 binding titres were
expressed as a reciprocal of the maximum serum dilution
which produced absorbance values that were three times
greater than the corresponding pre-bleed serum diluted at
1:50. To calculate the statistical significance of the final
bleed anti-VP2 responses between the vaccines and the
negative control, a Kruskal-Wallis (KW) test was per-
formed (due to non-normal and heteroscedastic data) to
compare medians among groups. Statistical analysis was
carried out using STATISTICA 64 (StatSoft, Inc.).
Western blot detection with Zera®-VP2ep and Zera®-VP2
mouse serum
The E. coli-produced BTV-8 VP2 antigen was separated on
8% SDS polyacrylamide gels and western blots were carried
out as described above. Individual pre- and final bleed sera
from both repeat immunization experiments were pooled
into vaccine groups (5 mice per vaccine) and diluted 1:100
in blocking buffer for detection of E. coli-produced VP2.
1:100 BTV-8 VLP sheep serum was used as positive control
[20]. Sera was detected with either anti-mouse IgG or anti-
goat/sheep alkaline phosphatase-conjugated secondary anti-
bodies, respectively.
Additional files
Additional file 1: Figure S2. Schematic representation of the Zera®-
fused constructs. (a) pEAQ-HTZera®-VP2ep, and (c) pEAQ-HTZera®-VP2. The
pEAQ-HTZera® (MluI / XhoI) backbone is shown in (b). Zera® is
represented by the pink box, the linker sequence by the blue box and
VP2ep and VP2 are represented by the green and orange boxes,
respectively. (PPTX 38 kb)
Additional file 2: Figure S1. Schematic representation of the primers
used to create the fusion product Zera®-VP2ep by assembly PCR. (PPTX 33 kb)
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